REFERENCES
1. Benson MD, Buxbaum JN, Eisenberg DS, et al. Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2020;27:217-22.
2. Porcari A, Merlo M, Rapezzi C, Sinagra G. Transthyretin amyloid cardiomyopathy: an uncharted territory awaiting discovery. Eur J Intern Med 2020;82:7-15.
3. Maurer MS, Bokhari S, Damy T, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail 2019;12:e006075.
4. Emdin M, Aimo A, Rapezzi C, et al. Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart J 2019;40:3699-706.
5. Merlo M, Porcari A, Pagura L, et al. A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization-the first insight from the AC-TIVE Study. Eur J Prev Cardiol 2021;zwab127.
6. Kastritis E, Palladini G, Minnema MC, et al. ANDROMEDA Trial Investigators. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 2021;385:46-58.
7. Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol 2016;67:2941-8.
8. Maurer MS, Schwartz JH, Gundapaneni B, et al. ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018;379:1007-16.
9. Korosoglou G, Giusca S, André F, et al. Diagnostic work-up of cardiac amyloidosis using cardiovascular imaging: current standards and practical algorithms. Vasc Health Risk Manag 2021;17:661-73.
10. Porcari A, Falco L, Lio V, et al. Cardiac amyloidosis: do not forget to look for it. Eur Heart J Suppl 2020;22:E142-7.
11. González-López E, Gallego-Delgado M, Guzzo-Merello G, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015;36:2585-94.
12. Porcari A, Pagura L, Longo F, et al. Prognostic significance of unexplained left ventricular hypertrophy in patients undergoing carpal tunnel surgery. ESC Heart Fail 2021; doi: 10.1002/ehf2.13606.
13. Castaño A, Narotsky DL, Hamid N, et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 2017;38:2879-87.
14. Nietlispach F, Webb JG, Ye J, et al. Pathology of transcatheter valve therapy. JACC Cardiovasc Interv 2012;5:582-90.
15. Visser RAB, Gravenor C, Ahmed S, Harky A. Amyloidosis and cardiovascular diseases: a clinical insight. J Card Surg 2021;36:522-9.
16. Porcari A, Bussani R, Merlo M, et al. Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination. Front Cardiovasc Med 2021;8:1680.
17. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004;94:1008-10.
18. Koike H, Katsuno M. The ultrastructure of tissue damage by amyloid fibrils. Molecules 2021;26:4611.
19. Koike H, Katsuno M. Transthyretin amyloidosis: update on the clinical spectrum, pathogenesis, and disease-modifying therapies. Neurol Ther 2020;9:317-33.
20. Mendes Sousa M, Cardoso I, Fernandes R, Guimarães A, Saraiva MJ. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy. Am J Pathol 2001;159:1993-2000.
21. Kittleson MM, Maurer MS, Ambardekar AV, et al. American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the american heart association. Circulation 2020;142:e7-e22.
22. Knight DS, Zumbo G, Barcella W, et al. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. JACC Cardiovasc Imaging 2019;12:823-33.
23. Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol 2016;68:1323-41.
24. Rapezzi C, Lorenzini M, Longhi S, et al. Cardiac amyloidosis: the great pretender. Heart Fail Rev 2015;20:117-24.
25. Canepa M, Tini G, Musumeci B, et al. Real-world versus trial patients with transthyretin amyloid cardiomyopathy. Eur J Heart Fail 2019;21:1479-81.
26. Tini G, Cappelli F, Biagini E, et al. Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey. ESC Heart Fail 2021;8:3369-74.
27. Aimo A, Vergaro G, Castiglione V, Rapezzi C, Emdin M. Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis. Eur J Intern Med 2020;80:66-72.
28. Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid 2017;24:132-3.
29. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357-77.
30. Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail 2018;5:772-9.
31. Donnellan E, Wazni OM, Hanna M, et al. Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence, and efficacy of rhythm control strategies. JACC Clin Electrophysiol 2020;6:1118-27.
32. Feng D, Edwards WD, Oh JK, et al. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007;116:2420-6.
33. Hindricks G, Potpara T, Dagres N, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373-498.
34. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981;63:1285-8.
35. Muchtar E, Gertz MA, Kumar SK, et al. Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use? Amyloid 2018;25:86-92.
36. Cheung CC, Roston TM, Andrade JG, Bennett MT, Davis MK. Arrhythmias in cardiac amyloidosis: challenges in risk stratification and treatment. Can J Cardiol 2020;36:416-23.
37. Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA. Selective binding of nifedipine to amylold fibrils. Am J Cardiol 1985;55:1646.
38. Gertz MA, Falk RH, Skinner M, Cohen AS, Kyle RA. Worsening of congestive heart failure in amyloid heart disease treated by calcium channel-blocking agents. Am J Cardiol 1985;55:1645.
39. Martinez-Naharro A, Gonzalez-Lopez E, Corovic A, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. J Am Coll Cardiol 2019;73:1733-4.
40. El-Am EA, Dispenzieri A, Melduni RM, et al. Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis. J Am Coll Cardiol 2019;73:589-97.
41. Loungani RS, Rehorn MR, Geurink KR, et al. Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. Am Heart J 2020;222:26-9.
42. Tan NY, Mohsin Y, Hodge DO, et al. Catheter ablation for atrial arrhythmias in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 2016;27:1167-73.
43. Barbhaiya CR, Kumar S, Baldinger SH, et al. Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy. Heart Rhythm 2016;13:383-90.
44. Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018;39:2799-806.
45. Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines, and the heart rhythm society. J Am Coll Cardiol 2019;74:932-87.
46. Donnellan E, Wazni OM, Saliba WI, et al. Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality. J Cardiovasc Electrophysiol 2019;30:2427-32.
47. Dubrey S, Pollak A, Skinner M, Falk RH. Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 1995;74:541-4.
48. Cappelli F, Tini G, Russo D, et al. Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid 2021;28:12-8.
49. Yarmohammadi H, Varr BC, Puwanant S, et al. Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy). Am J Cardiol 2012;110:222-6.
50. Donnellan E, Elshazly MB, Vakamudi S, et al. No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis. JACC Clin Electrophysiol 2019;5:1473-4.
51. Feng D, Syed IS, Martinez M, et al. Intracardiac thrombosis and anticoagulation therapy in cardiac amyloidosis. Circulation 2009;119:2490-7.
52. Santarone M, Corrado G, Tagliagambe LM, et al. Atrial thrombosis in cardiac amyloidosis: diagnostic contribution of transesophageal echocardiography. J Am Soc Echocardiogr 1999;12:533-6.
53. Parsons C, Patel SI, Cha S, et al. CHA2DS2-VASc score: a predictor of thromboembolic events and mortality in patients with an implantable monitoring device without atrial fibrillation. Mayo Clin Proc 2017;92:360-9.
54. Ternacle J, Krapf L, Mohty D, et al. Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J Am Coll Cardiol 2019;74:2638-51.
55. Galat A, Guellich A, Bodez D, et al. Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J 2016;37:3525-31.
56. Treibel TA, Fontana M, Gilbertson JA, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 2016;9:e005066.
57. Sperry BW, Jones BM, Vranian MN, Hanna M, Jaber WA. Recognizing transthyretin cardiac amyloidosis in patients with aortic stenosis: impact on prognosis. JACC Cardiovasc Imaging 2016;9:904-6.
59. Monticelli FC, Kunz SN, Keller T, Bleiziffer S. Cardiac amyloidosis as a potential risk factor for transapical transcatheter aortic valve implantation. J Card Surg 2014;29:623-4.
60. Moreno R, Dobarro D, López de Sá E, et al. Cause of complete atrioventricular block after percutaneous aortic valve implantation: insights from a necropsy study. Circulation 2009;120:e29-30.
61. Dubrey SW, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-57.
62. Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm 2014;11:158-62.
63. Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol 2009;104:990-4.
64. Palladini G, Malamani G, Cò F, et al. Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 2001;24:1228-33.
65. Giancaterino S, Urey MA, Darden D, Hsu JC. Management of arrhythmias in cardiac amyloidosis. JACC Clin Electrophysiol 2020;6:351-61.
66. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015;36:2793-867.
67. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2018;15:e190-252.
68. Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
69. Hamon D, Algalarrondo V, Gandjbakhch E, et al. Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis. Int J Cardiol 2016;222:562-8.
70. Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA. Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 2013;24:793-8.
71. Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008;5:235-40.
72. Sayed RH, Rogers D, Khan F, et al. A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J 2015;36:1098-105.
73. Escher F, Senoner M, Doerler J, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol 2020;109:78-88.
74. Damy T, Jaccard A, Guellich A, et al. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. Amyloid 2016;23:194-202.
75. Donnellan E, Wazni OM, Hanna M, Kanj M, Saliba WI, Jaber WA. Cardiac resynchronization therapy for transthyretin cardiac amyloidosis. J Am Heart Assoc 2020;9:e017335.
